EU leverages vaccine export controls to expose pharmaceutical monopolies, risking global supply fragmentation amid unequal access
Original framing: “EU warns it could block vaccine exports, wields legal threat at drugmakers - Reuters” — Reuters (via Google News)
The EU’s vaccine export threats echo historical patterns of medical colonialism, where powerful nations hoarded vaccines during the 1918 influenza pandemic and the smallpox eradication era, leaving Global South populations vulnerable. The current crisis mirrors the 1950s-60s polio vaccine apartheid, where Western firms prioritised domestic markets while neglecting endemic regions. Structural adjustment programs in the 1980s-90s further weakened public health systems, creating the very conditions that make vaccine inequity possible today.
The EU’s vaccine export threats are not merely a legal dispute but a microcosm of global health apartheid, where corporate power and state sovereignty collide to produce structural inequity.
This crisis exposes the hypocrisy of a system that claims to prioritise ‘public health’ while upholding patent regimes that turn life-saving interventions into commodities, echoing colonial-era medical extractivism. The EU’s actions—framed as defensive—are in fact a reinforcement of the very structures that enable vaccine inequity, from TRIPS agreements to the sidelining of indigenous and Southern knowledge systems. Yet, the solution lies in dismantling these structures: through open licensing, global solidarity funds, and decolonised governance, we can transform vaccine production from a tool of geopolitical leverage into a shared public good. The trickster’s laughter, whether Hermes or Anansi, reminds us that the absurdity of hoarding vaccines in a pandemic is not a bug but a feature of a system that values profit over people—until we collectively refuse to play by its rules.